Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

The conversation is about comparing the effectiveness of fluridil and clascoterone in preventing hair loss and inquiring about their use as standalone treatments. There is a question about the concentration of the fluridil brand for efficacy.

Avixis Alfatradiol is a topical 5-alpha reductase inhibitor available in Latin America and Germany, but its effectiveness is questioned. A user reported worsened hair loss after using it and recommended finasteride instead due to its proven effectiveness and lower cost.

Pelage PP405 is a new hair loss treatment in trials, potentially reactivating dormant hair follicles without affecting hormones. Results are expected in February 2025, offering an alternative to minoxidil and finasteride.

PTD-DBM is being explored for hair regrowth by targeting CXXC5, with clinical trials expected after pre-clinical studies. Users express anticipation and skepticism about its effectiveness.

The conversation is about obtaining dutasteride in Tunisia, with questions about its availability, prescription requirements, and cost. Finasteride is available in Algeria, but dutasteride is not.

Dutasteride users have mixed results in hair loss treatment, with some experiencing improvements and others worsening. Some report metabolic changes like weight gain or diabetes, while others have no significant side effects.

People in India are discussing ordering Kintor's KX-826 for hair loss treatment. They also mention sourcing RU58841 from reliable suppliers.

Winlevi (clascoterone 1%) is being discussed as a potential hair loss treatment. Users are considering its use despite concerns about its delivery method.

A user is seeking a titanium dioxide-free finasteride pill due to health concerns. They have not found a suitable supplier yet.

The user is concerned about hair loss despite taking finasteride and has a hair transplant scheduled. They experience scalp itching and burning, which hasn't been relieved by various treatments, and another user suggests using ghk-cu & ahk-cu serum and Koshine kx-826/pyrilutamide for relief.

The conversation is about interest in watching the Pelage PP405 presentation online, with mentions of hair loss treatments like finasteride. Users express frustration and humor about the topic, with one user noting finasteride caused discomfort.

GT20029 showed significant hair growth and safety in phase II trials, with no adverse sexual events. Users are hopeful but concerned about future costs and systemic effects.

The conversation discusses hair loss treatments, specifically using finasteride pills, RU58841 topically, and dermarolling twice a week. The user also mentions considering minoxidil and addressing a vitamin D deficiency, which may have contributed to reduced hair shedding.

The conversation is about the lack of updates on GT20029, a potential hair loss treatment, and the user considering using dutasteride or RU58841 instead of minoxidil/finasteride due to the long duration of the latter treatments.

A breakthrough in hair follicle cultivation using induced pluripotent stem cells (iPSCs) has been achieved, producing large hair follicles suitable for transplantation. Clinical trials for this hair multiplication technology are planned in partnership with Yinguan Biotechnology.

The user has been using kx826 for 10 months and topical minoxidil for 2 years, reporting slow but undeniable progress in hair regrowth. They experienced side effects from finasteride and do not use it.

Hair loss treatments, including PP405, minoxidil, finasteride, and RU58841, with hopes for future solutions. Participants discuss the emotional impact of hair loss and consider alternatives like hair transplants or acceptance.

The conversation is about hair regrowth progress using hormone replacement therapy (HRT) with Estradiol and Cyproterone, without using Minoxidil. The user shares progress pictures over 0, 3, and 6 months.

The conversation discusses reliable brands for RU58841, with recommendations for RUdirect and Receptorchem. Users also mention Anageninc as a known option for RU58841 in Europe and the UK.

The conversation discusses hair loss treatments, including finasteride, microneedling, minoxidil, and PTD-DBM. The user has not noticed significant regrowth and is considering cost-effective options like valproic acid.

The conversation discusses the lack of updates on GT20029 for hair loss treatment, with some users noting recent reports indicating ongoing data collection. There are mentions of other treatments like Pyrilutamide and Minoxidil.

Kintor announced Phase 3 results for pyrilutamide, a hair loss treatment, in China. The conversation is focused on this announcement and its implications for hair loss treatment.

A user shared their 7-month hair transformation using Dutasteride 0.5 mg three times a week. They reported no side effects and improved hair, using Avodart as monotherapy.

The user reports progress in hair regrowth using a daily routine of 0.5mg Dutasteride, 5% Minoxidil foam, and Olly hair gummies, while discontinuing rosemary water. They are hopeful for continued improvement and have received positive feedback on their progress.

The conversation discusses hair loss, genetics, and treatments like Dutasteride. It highlights the influence of genetics on hair loss, noting that indigenous people are less prone to it.

A 16-year-old is experiencing hair loss and is using minoxidil, finasteride, and plans to add RU58841, while considering other treatments like MK-677 and microneedling. Concerns are raised about the potential impact of these treatments on puberty and development.

Finasteride and dutasteride can cause muted orgasms and reduced sensation, possibly due to hormonal imbalances like increased estrogen or reduced DHT. Some users report improvement by adjusting dosages or stopping the medication.

A user had 4000 hair grafts in Denmark and started taking 0.5mg finasteride daily, reporting good progress after four months. The procedure cost 55,000 DKK (7,400 euros) and the user is pleased with the results, especially in the temples and crown areas.

GT20029 is an experimental topical treatment for male-pattern hair loss, showing promising results in Phase 2 trials and moving towards Phase 3. It aims to degrade androgen receptors in hair follicles, differing from treatments like finasteride and minoxidil.

Taking dutasteride with a meal containing fat may improve absorption, but consistency in routine is more important than timing. Minor variations in absorption won't significantly affect efficacy due to dutasteride's long half-life.